Project Grant R01DK149491
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Colorado State University $775,317 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on August 20, 2026. The research project investigates the role of fecal metabolites in infant growth and overweight risk during complementary feeding (the period from approximately five to twenty-four months when infants consume foods beyond breastmilk or formula). The work aims to elucidate...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University $1.638 million on September 11, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research using continuous glucose monitoring systems and machine learning methods to identify glucose pattern clusters and high-risk subgroups in persons with and without diabetes. The project, titled "Glucose Patterns and Clinical Outcomes in the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Pennington Biomedical Research Center $731,916 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a prospective longitudinal study characterizing infant energy balance from one to twelve months of age. The study will enroll 100 healthy infants and assess them at one, three, six, nine, and twelve months using gold-standard methods adapted for...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Southern California $845,922 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate gut-brain pathways in childhood obesity and type 2 diabetes development. The research integrates neuroimaging, gut hormone measures, metabolic profiling, and lifestyle assessments in a longitudinal cohort of children ages 7 to 16 years, examining how...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Illinois $160,575 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant K01DK147658). The award funds a three-year study of Medicaid alternative payment model (APM) implementation and evidence-based practice adoption in federally qualified health centers (FQHCs) to improve diabetes outcomes. The research addresses how FQHCs, which...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham & Women's Hospital $891,382 on May 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a multisite evaluation of continuous glucose monitoring (CGM) effectiveness in older adults with type 2 diabetes. The recipient will assess how CGM-derived metrics influence clinician behavior and therapeutic decision-making, compare clinical outcomes and care...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital Corporation (doing business as Boston Children's Hospital) $600,147 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the efficacy of a novel bile acid-binding blenderized gastrostomy tube feed for children with medical complexity at risk for aspiration-associated complications. The research addresses the clinical...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Kansas Medical Center Research Institute, Inc. $132,180 on July 3, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Project Grant K01DK144673) to conduct research assessing the role of gastrointestinal mechanosensation in the regulation of feeding behavior and glucose homeostasis. The research investigates how vagal afferent neurons that express...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Regents of the University of Colorado (University of Colorado-Denver) $248,965 on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds a project grant (R00DK136503) investigating pancreatic fat and volume as metabolic risk factors in childhood, leveraging the longitudinal Healthy Start Study cohort of approximately 1,400 mother-child pairs in...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $412,992 on May 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct the Surveillance of Nutritional Risk for Acute Kidney Injury in Critically Ill Kids (SNACK) study. The study evaluates whether poor baseline nutritional status is a modifiable risk factor for acute kidney injury in pediatric intensive care unit patients. The research...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Children's Mercy Hospital $532,087 on August 28, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to examine the association between added sugar exposure in infant formula and complementary foods and glucose variability during early childhood. The award funds a prospective cohort study recruiting 200 infants at three months of age and following them through 24 months to evaluate whether higher added sugar intake correlates with greater glucose variability and excessive weight gain. The study will conduct continuous glucose monitoring using the Dexcom G7 system at three, six, and twelve months of age, measuring mean glucose concentration, mean amplitude of glycemic excursions (MAGE), and percent coefficient of variation (CV). At each timepoint, researchers will collect infant anthropometrics (weight and length) and dietary intake via three-day caregiver-reported dietary records. A follow-up assessment at 24 months will evaluate obesity risk. The research hypothesis links early added sugar exposure to increased glucose variability as an early marker of metabolic dysfunction and examines whether this pattern predicts later obesity. The period of performance runs from August 28, 2026, through June 30, 2031. Work is performed in Kansas City, Missouri.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $532.1k | 8/28/26 |